Abstract
Pregnant women with late latent or latent of unknown duration syphilis are recommended to receive three doses of benzathine penicillin G each 9 or fewer days apart; data on interval variations are limited. We found no significant difference in risk of congenital syphilis between 9-day and 6-8 day dosing intervals.
Summary Among pregnant women with late latent or latent of unknown duration syphilis, there was no difference in risk of congenital syphilis between 9-day and 6-8 day maternal treatment dosing intervals.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This activity was reviewed by CDC and conducted consistent with applicable federal law and policy (45 C.F.R. part 46.102(l)(2), 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a). It was deemed public health surveillance and exempt from IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding/Support: This study was performed as regular work of the Centers for Disease Control and Prevention (CDC) and is supported by the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreements (CDC-RFA-CK19-1904 and CDC-RFA-CK24-0002), Division of Birth Defects and Infant Disorders Cooperative Agreement (CDC-RFA-DD-23-0003), and through contractual mechanisms, including the Local Health Department Initiative to Chickasaw Health Consulting (200-2021-F-12655).
Disclosure: The authors of this manuscript have no conflicts of interest to disclose. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Authors used the CDC-developed PART AI tool based on ChatGPT (OpenAI, San Francisco, CA; GPT-5.5 Thinking), to check manuscript adherence to the CDC Domains of Excellence Framework for High-Quality Public Health Science. Authors reviewed all output and are responsible for accuracy, integrity, interpretation, and final content.
Data Availability
These data are collected under relevant provisions of the Public Health Service Act and are protected at CDC by an Assurance of Confidentiality (Section 308(d) of the Public Health Service Act, 42 U.S.C. 242 m(d))(https://www.cdc.gov/od/science/integrity/confidentiality/), which prohibits use or disclosure of any identifiable or potentially identifiable information collected under the Assurance for purposes other than those set out in the Assurance. Requests for access will be considered on a case by case basis, and inquiries should be directed to setnet{at}cdc.gov.





